Recursion Pharmaceuticals (RXRX) Research & Development: 2020-2025
Historic Research & Development for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to $121.1 million.
- Recursion Pharmaceuticals' Research & Development rose 62.28% to $121.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $477.7 million, marking a year-over-year increase of 67.27%. This contributed to the annual value of $314.4 million for FY2024, which is 30.34% up from last year.
- According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Research & Development is $121.1 million, which was down 5.89% from $128.6 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Research & Development registered a high of $129.6 million during Q1 2025, and its lowest value of $24.1 million during Q1 2021.
- For the 3-year period, Recursion Pharmaceuticals' Research & Development averaged around $85.0 million, with its median value being $73.9 million (2024).
- As far as peak fluctuations go, Recursion Pharmaceuticals' Research & Development skyrocketed by 133.32% in 2021, and later declined by 8.93% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' Research & Development (Quarterly) stood at $48.3 million in 2021, then fell by 8.93% to $44.0 million in 2022, then skyrocketed by 57.99% to $69.5 million in 2023, then soared by 41.52% to $98.3 million in 2024, then surged by 62.28% to $121.1 million in 2025.
- Its Research & Development stands at $121.1 million for Q3 2025, versus $128.6 million for Q2 2025 and $129.6 million for Q1 2025.